Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label extension study of subcutaneous efgartigimod PH20 in adults with bullous pemphigoid
CTR20233696Phase 3Completed
- Sponsor
- argenx
- Start
- Feb 2024
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Therapeutic Enzymes → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of efgartigimod alfa + hyaluronidase-qvfc in Bullous Pemphigoid (BP), sponsored by argenx. Started Feb 2024; status: completed.
02
Drugs
efgartigimod alfa + hyaluronidase-qvfc
03
Conditions
Bullous Pemphigoid (BP)
Beyond the preview
Go deeper on CTR20233696.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20233696.